Welcome

Alzheimer Europe’s April 2022 newsletter brings you the latest news on developments in the dementia field, across Europe and beyond.

 

Summaries of a few of our top stories appear below.

 

Our monthly newsletter reaches around 11,000 people and we are always happy to receive feedback, or suggestions regarding news items to share.

 
22 April: Biogen withdraws marketing authorisation application for aducanumab

On 22 April 2022, Biogen announced that it had notified the European Medicines Agency about the withdrawal of its marketing authorisation application for aducanumab, for the treatment of early Alzheimer’s disease.
26 April: Alzheimer Europe hosts Academy session on giving a voice to people with dementia

On 26 April 2022, Alzheimer Europe held an online session of its popular Alzheimer's Association Academy series, bringing together representatives of its member organisations, the European Working Group of People with Dementia, pharmaceutical companies and researchers. The topic for this session was "giving a voice to people with dementia".
28 April: Alzheimer Europe signs Memorandum of Understanding with European Association of Service Providers for Persons with Disabilities

On 28 April 2022, Alzheimer Europe and the European Association of Service Providers for Persons with Disabilities (EASPD) signed a Memorandum of Understanding, to provide the basis for future collaboration.


29 April: Call for abstracts for the 32nd Alzheimer Europe Conference closing soon!

The call for abstracts for the 32nd Alzheimer Europe Conference (#32AEC), "Building Bridges”, which will take place in Bucharest, Romania, from 17 to 19 October 2022, will soon close. The deadline for submissions is 15 May 2022.